Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02953639 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 214
- Enrollment target
NCT02953639 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 214 participants.
The verdict
NCT02953639, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 214 participants
- Enrollment target
Study Summary
This multicenter study assessed the effects of 24 weeks of basmisanil treatment on cognition and functioning of stable schizophrenia participants treated with antipsychotics.
Interventions
- DRUG Placebo
- DRUG Basmisanil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 214 participants |
| Start Date | 2016-11-30 |
| Est. Completion | 2019-12-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02953639
The ClinicalTrials.gov registry entry for NCT02953639 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 214 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02953639 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02953639 about?
NCT02953639 is a clinical study titled "A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics". This multicenter study assessed the effects of 24 weeks of basmisanil treatment on cognition and functioning of stable schizophrenia participants treated with antipsychotics.
What is the current status of trial NCT02953639?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 214 participants. The study started on 2016-11-30. Estimated completion is 2019-12-12.
What interventions are being tested in trial NCT02953639?
The interventions under investigation include: Placebo (DRUG), Basmisanil (DRUG).
Who is sponsoring clinical trial NCT02953639?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.